Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013
Dec 2, 2018 - Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients -
|
Nov 8, 2018 -- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End --
|
MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments
|
Aug 30, 2018 -Fiscal Year 2018 Highlighted by Progress Across All Four Clinical-stage Oncology Candidates; ME-401 Accelerated Approval Study to Start by Year-end 2018-
|
--Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end--
|
Jun 4, 2018 -- 90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies --
|
Jun 4, 2018 -- ME-344 Mitochondrial Inhibitor in Combination with Avastin Demonstrates Inhibition of Tumor Proliferation in HER2 Negative Breast Cancer Patients --
|
